Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NALA: Neratinib vs Lapatinib in HER2+ MBC
NCT01808573Phase 3Completed
- Sponsor
- Puma Biotechnology, Inc.
- Start
- Mar 2013
- Primary completion
- Sep 2018
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 28
01
Overview
A Phase 3 trial of neratinib in HER2-positive metastatic breast cancer, sponsored by Puma Biotechnology, Inc.. Started Mar 2013; status: completed.
02
Drugs
neratinib
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT01808573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01808573.